BELLUS Health Inc logo

BLU - BELLUS Health Inc Share Price

$8.77 0.2  2.0%

Last Trade - 17/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £374.5m
Enterprise Value £296.8m
Revenue £20.6k
Position in Universe 3047th / 6415
Bullish
Bearish
Unlock BLU Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BLU Revenue Unlock BLU Revenue

Net Income

BLU Net Income Unlock BLU Revenue

Normalised EPS

BLU Normalised EPS Unlock BLU Revenue

PE Ratio Range

BLU PE Ratio Range Unlock BLU Revenue

Dividend Yield Range

BLU Dividend Yield Range Unlock BLU Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BLU EPS Forecasts Unlock BLU Revenue
Profile Summary

BELLUS Health Inc is a Canada-based biopharmaceutical development company. The Company's pipeline of projects includes the BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs. BLU-5937 is a potent, selective, orally bio-available small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to help a number of chronic cough patients who do not respond to current therapies. BELLUS Health Inc also has economic interests in other partnered clinical-stage drug development programs, including KIACTA for sarcoidosis, AMO-01 for Fragile X Syndrome and ALZ-801 for APOE4 homozygous Alzheimer’s disease.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated April 12, 2012
Public Since September 15, 2014
No. of Shareholders: n/a
No. of Employees: 9
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market (Dual Listing)
Shares in Issue 55,378,660
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BLU Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to BLU
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.